ResearcherVaximm (Germany)No recent work listed
Andreas G. Niethammer
Matched on OpenAlex author ID A5000135035. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper
Papers 2
- Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlle… Co-author DOI 10.1080/2162402x.2014.1001217↗
- Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients… Co-author DOI 10.1186/1471-2407-12-361↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Friedrich Hubertus Schmitz-Winnenthal · 2 shared papers, 2012–2015 · strength 0.06
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Nicolas Hohmann · 2 shared papers, 2012–2015 · strength 0.06
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Philipp Beckhove · 2 shared papers, 2012–2015 · strength 0.06
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Lars Grenacher · 2 shared papers, 2012–2015 · strength 0.06
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Jürgen Weitz · 2 shared papers, 2012–2015 · strength 0.06
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Frank Pianka · 1 shared paper, 2015 · strength 0.03
- Thomas Schmidt · 1 shared paper, 2015 · strength 0.03
- Ulla Klaiber · 1 shared paper, 2015 · strength 0.03
- Markus K. Diener · 1 shared paper, 2015 · strength 0.03
- Alexis B. Ulrich · 1 shared paper, 2015 · strength 0.03
- Christoph Springfeld · 1 shared paper, 2015 · strength 0.03
- Markus Wolfgang Büchler · 1 shared paper, 2012 · strength 0.03
- Moritz Koch · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.